Evidence map›Paper›PMID 35831763›Full record

SynthesisJournal of cancer research and clinical oncology2023

Effects of SARS-CoV-2 infections in patients with cancer on mortality, ICU admission and incidence: a systematic review with meta-analysis involving 709,908 participants and 31,732 cancer patients.

Mehmet Emin Arayici, Nazlican Kipcak, Ufuktan Kayacik, Cansu Kelbat, Deniz Keskin, Muhammed Emin Kilicarslan, Ahmet Veli Kilinc, Sumeyye Kirgoz, Anil Kirilmaz, Melih Alihan Kizilkaya and 7 more

Open access · bronzeAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. [Incidence of COVID-19 in cancer patients from the HIGA Alende, Mar del Plata, Argentina, 2020-2021]Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Mehmet Emin ArayiciDepartment of Preventive Oncology, Institute of Health Sciences, Dokuz Eylul University, 15 July Medicine and Art Campus, Inciralti-Balcova 35340, Izmir, Turkey. mehmet.e.arayici@gmail.com.ORCID http://orcid.org/0000-0002-0492-5129
Nazlican KipcakDepartment of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.ORCID http://orcid.org/0000-0001-6718-8704
Ufuktan KayacikDepartment of Biostatistics and Medical Informatics, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.ORCID http://orcid.org/0000-0002-8880-8623
Cansu KelbatDepartment of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.ORCID http://orcid.org/0000-0002-6347-6650
Deniz KeskinDepartment of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.ORCID http://orcid.org/0000-0001-9451-1263
Muhammed Emin KilicarslanDepartment of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.ORCID http://orcid.org/0000-0002-0897-7364
Ahmet Veli KilincDepartment of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.ORCID http://orcid.org/0000-0001-5612-4959
Sumeyye KirgozDepartment of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.ORCID http://orcid.org/0000-0002-3725-2223
Anil KirilmazDepartment of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.ORCID http://orcid.org/0000-0002-6408-1941
Melih Alihan KizilkayaDepartment of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.ORCID http://orcid.org/0000-0002-4014-0070
Irem Gaye KizmazDepartment of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.ORCID http://orcid.org/0000-0001-9454-7039
Enes Berkin KocakDepartment of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.ORCID http://orcid.org/0000-0002-7889-082X
Enver KochanDepartment of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.ORCID http://orcid.org/0000-0001-6746-3243
Begum KocpinarDepartment of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.ORCID http://orcid.org/0000-0002-8242-7221
Fatmanur KordonDepartment of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.ORCID http://orcid.org/0000-0002-5149-5109
Batuhan KurtDepartment of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.ORCID http://orcid.org/0000-0002-8637-3136
Hulya EllidokuzDepartment of Biostatistics and Medical Informatics, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.ORCID http://orcid.org/0000-0001-8503-061X
Dokuz Eylül University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer patients constitute one of the highest-risk patient groups during the COVID-19 pandemic. In this study, it was aimed to perform a systematic review and meta-analysis to determine both the incidence and ICU (Intensive Care Unit) admission rates and mortality in SARS-CoV-2 infected cancer patients.

methodsThe PRISMA guidelines were closely followed during the design, analysis, and reporting of this systematic review and meta-analysis. A comprehensive literature search was performed for the published papers in PubMed/Medline, Scopus, medRxiv, Embase, and Web of Science (WoS) databases. SARS-CoV-2 infection pooled incidence in the cancer populations and the risk ratio (RR) of ICU admission rates/mortality in cancer and non-cancer groups, with 95% confidence intervals (CIs), were calculated using the random-effects model.

resultsA total of 58 studies, involving 709,908 participants and 31,732 cancer patients, were included in this study. The incidence in cancer patients was calculated as 8% (95% CI: 8-9%). Analysis results showed that mortality and ICU admission rate was significantly higher in patients with cancer (RR = 2.26, 95% CI: 1.94-2.62, P < 0.001; RR = 1.45, 95% CI: 1.28-1.64, p < 0.001, respectively).

conclusionAs a result, cancer was an important comorbidity and risk factor for all SARS-CoV-2 infected patients. This infection could result in severe and even fatal events in cancer patients. Cancer is associated with a poor prognosis in the COVID-19 pandemic. Cancer patients should be assessed more sensitively in the COVID-19 outbreak.

Indexed as

COVID-19NeoplasmsHospitalizationHumansIntensive Care UnitsPandemicsSARS-CoV-2CancerICU admissionMortalitySARS-CoV-2

Identifiers

PMID35831763
PMCPMC9281353
OpenAlexW4285394722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.